Skip to main content

Compounders lose battle over Eli Lilly weight loss drug and FDA shortage list

By STAT News  
   May 08, 2025

A federal judge has sided with the FDA over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.

Full story


Get the latest on healthcare leadership in your inbox.